Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
GLP-1 medications, once flagged for psychiatric safety concerns, are now showing significant benefits for patients with serious mental illness (SMI). New research links GLP-1 use to a 24% reduction in all-cause mortality in SMI patients over 4 years, along with lower rates of bipolar hospitalization and substance use disorder. Clinicians are encouraged to prescribe thoughtfully — prioritizing psychiatric stability and cross-specialty communication.
GLP-1 receptor agonists, once shadowed by early warnings about suicidal ideation, are now emerging as potentially life-saving tools for patients with serious mental illnesses (SMI) like major depressive disorder, bipolar disorder, and schizophrenia. A growing body of research shows not only that these drugs are psychiatrically safe, but that they may actively improve outcomes for one of medicine's most vulnerable populations.
A large meta-analysis in JAMA Psychiatry found no link between GLP-1 use and serious psychiatric adverse events or worsening depression — and even noted modest quality-of-life improvements. Meanwhile, a retrospective study analyzing over 1.5 million matched adults found that SMI patients on GLP-1s had a 24% lower risk of dying from any cause over 4 years compared to those on SGLT2 inhibitors, plus significantly fewer major cardiovascular events.
By the Numbers:
Why it matters: People with SMI face a staggering mortality gap driven by cardiometabolic disease — and GLP-1s could help close it. For primary care providers increasingly managing patients with complex psychiatric histories, understanding how to counsel patients and coordinate with psychiatrists on GLP-1 use is becoming an essential clinical skill.
